{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T01:16:51Z","timestamp":1772414211011,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jval.2019.12.003","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T20:33:46Z","timestamp":1581539626000},"page":"461-470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France"],"prefix":"10.1016","volume":"23","author":[{"given":"Salah","family":"Ghabri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aymeric","family":"Binard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves-Marie","family":"Pers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Maunoury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Jaime","family":"Caro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jval.2019.12.003_bib3","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/ard.2004.029199","article-title":"Prevalence of rheumatoid arthritis in France: 2001","volume":"64","author":"Guillemin","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"10.1016\/j.jval.2019.12.003_bib5","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s40265-018-1009-0","article-title":"Why biologics and biosimilars remain so expensive: despite two wins for biosimilars, the Supreme Court\u2019s recent rulings do not solve fundamental barriers to competition","volume":"78","author":"Chen","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jval.2019.12.003_bib6","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.3389\/fphar.2018.01070","article-title":"Comparative price analysis of biological products for treatment of rheumatoid arthritis","volume":"9","author":"Manova","year":"2018","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jval.2019.12.003_bib7","first-page":"1","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jval.2019.12.003_bib8","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jval.2019.12.003_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbspin.2018.10.002","article-title":"Update of French Society for Rheumatology recommendations for managing rheumatoid arthritis","volume":"86","author":"Daien","year":"2019","journal-title":"Joint Bone Spine"},{"issue":"7","key":"10.1016\/j.jval.2019.12.003_bib11","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40273-016-0394-z","article-title":"Discretely integrated condition event (DICE) simulation for pharmacoeconomics","volume":"34","author":"Caro","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2019.12.003_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0272989X17715636","article-title":"Adding events to a Markov model using DICE simulation","volume":"38","author":"Caro","year":"2018","journal-title":"Med Decis Making"},{"issue":"5 suppl 85","key":"10.1016\/j.jval.2019.12.003_bib13","article-title":"The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28)","volume":"32","author":"van Riel","year":"2014","journal-title":"Clin Exp Rheumat"},{"key":"10.1016\/j.jval.2019.12.003_bib14","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3899\/jrheum.190105","article-title":"OMERACT 2018: international consensus conference on outcome measures in rheumatology","volume":"46","author":"March","year":"2019","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.jval.2019.12.003_bib15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jbspin.2007.06.001","article-title":"The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients","volume":"74","author":"Combe","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jval.2019.12.003_bib16","article-title":"ESPOIR and the French database management: what have we learned from the first years of follow-up?","volume":"32","author":"Combe","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.jval.2019.12.003_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jbspin.2014.05.002","article-title":"Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis","volume":"81","author":"Gaujoux-Viala","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.jval.2019.12.003_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1017\/S0266462318003628","article-title":"Rheumatoid arthritis treated with 6-months of first-line biologic or biosimilar therapy: an updated systematic review and network meta-analysis","volume":"35","author":"Simpson","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"issue":"11","key":"10.1016\/j.jval.2019.12.003_bib22","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2016.13512","article-title":"Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial","volume":"316","author":"Gottenberg","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jval.2019.12.003_bib23","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jval.2019.12.003_bib24","series-title":"Targeted immune modulators for rheumatoid arthritis: effectiveness & value","year":"2017"},{"issue":"4","key":"10.1016\/j.jval.2019.12.003_bib27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00296-016-3638-5","article-title":"Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study","volume":"37","author":"van den Hoek","year":"2017","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.jval.2019.12.003_bib28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10198-011-0351-x","article-title":"Valuing EQ-5D using time trade-off in France","volume":"14","author":"Chevalier","year":"2013","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2019.12.003_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J\u00a0Health Econ"},{"key":"10.1016\/j.jval.2019.12.003_bib30","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","article-title":"The estimation of a preference-based measure of health from the SF-12","volume":"42","author":"Brazier","year":"2004","journal-title":"Med Care"},{"issue":"5","key":"10.1016\/j.jval.2019.12.003_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097077","article-title":"Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation\u2014an economic analysis based on the ESPOIR cohort","volume":"9","author":"Chevreul","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jval.2019.12.003_bib37","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1524-4733.2008.00358.x","article-title":"Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI)","volume":"11","author":"Barton","year":"2008","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2019.12.003_bib39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11926-014-0447-2","article-title":"Health economic modelling of treatment sequences for rheumatoid arthritis: a systematic review","volume":"16","author":"Tosh","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"10.1016\/j.jval.2019.12.003_bib40","first-page":"703","article-title":"Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators","volume":"20","author":"Jansen","year":"2017","journal-title":"J\u00a0Med Econ"},{"issue":"35","key":"10.1016\/j.jval.2019.12.003_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20350","volume":"20","author":"Stevenson","year":"2016","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jval.2019.12.003_bib42","series-title":"Drugs for the management of rheumatoid arthritis: clinical evaluation","year":"2018"},{"issue":"1","key":"10.1016\/j.jval.2019.12.003_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40273-016-0455-3","article-title":"Modeling treatment sequences in pharmacoeconomic models","volume":"35","author":"Zheng","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.jval.2019.12.003_bib44","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","article-title":"ISPOR-SMDM Modeling Good Research Practices Task Force. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force 6","volume":"15","author":"Briggs","year":"2012","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520300280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520300280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:18:35Z","timestamp":1761095915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520300280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1098301520300280"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2019.12.003","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2019.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}